Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc PFE and BioNTech SE BNTX announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-tailored bivalent COVID-19 vaccine against newer Omicron sublineages.
These data, posted on the preprint server bioRxiv, indicate that the companies' bivalent vaccine elicits a greater increase in neutralizing antibody titers than the companies' original COVID-19 vaccine against these emerging Omicron sublineages.
Related: Pfizer, BioNTech Start Work On Next-Gen COVID-19 Vaccine Candidate For Broader Protection.
One month after a 30-µg booster (fourth) dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibodies against BA.4.6 increased 11.1-fold, neutralizing antibodies against BA.2.75.2, BQ.1.1, and XBB.1 increased by 6.7-fold, 8.7-fold, and 4.8-fold, respectively.
By comparison, the neutralizing antibody titers against BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 following the original shot's booster dose increased 2.3-fold, 2.1-fold, 1.8-fold, and 1.5-fold, respectively.
Overall, the bivalent booster generated a greater increase in neutralizing antibodies against emerging Omicron sublineages than the original Pfizer-BioNTech COVID-19 vaccine.
Price Action: PFE shares are down 0.08% at $48.29, and BNTX stock is up 0.31% at $166.78 on the last check Friday.